Breast Cancer
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
From the Journals
Breast milk liquid biopsy under study for early-stage breast cancer detection
Just like taking a small blood sample from newborns in a heel-prick test to rule out metabolic diseases, milk samples could be taken from women...
From the Journals
Can a Mediterranean diet reduce breast cancer recurrence?
A growing body of evidence suggests that a better dietary quality may improve survival among patients with breast cancer, but whether diet impacts...
News from the FDA/CDC
FDA OKs capivasertib for certain advanced breast cancers
The FDA also approved a companion diagnostic device, the FoundationOne CDx assay, to identify patients who are eligible for treatment with...
From the Journals
False-positive mammography results and risk for cancer death
The analysis provides clues about which patients with false-positive mammography results will go on to develop breast cancer and “can be used to...
Conference Recap
Highlights in Early Breast Cancer From ESMO 2023
Highlights in early breast cancer from ESMO 2023 include 5-year results from KEYNOTE-522 in TNBC, pCR benefits in ER+/HER2-, and a genomic risk...
Opinion
An 88-year-old Black woman presented with 3 months duration of asymptomatic, violaceous patches on the left breast
The patient's history is significant for breast cancer.
Conference Coverage
Particulate pollution increases the risk for breast cancer
“There is now strong epidemiological and biological evidence for the link between PM2.5 particulate exposure and cancer ...”
From the Journals
Low vitamin D linked to paclitaxel-induced peripheral neuropathy
These results also “suggest that vitamin D supplementation in patients with lower levels of vitamin D may reduce peripheral neuropathy ...”
Conference Coverage
T-DXd benefits persist for HER2-low breast cancer
Extended follow-up of DESTINY-Breast04 confirms survival benefit of T-DXd for HER2-low advanced breast cancer.
Conference Coverage
Omitting surgery may be safe in early BC after neoadjuvant pCR
A small trial in early breast cancer has reported 100% disease-free survival at 3 years in women who skipped surgery following pathologic complete...